

EXHIBIT

Knoblauch-24

RL 12/2/2021


exhibiticker.com

Save up to

\$1,200 per year

toward your KADIAN® prescriptions.

- No expiration date
- Up to the first \$50 toward each prescription
- Up to 24 prescriptions over 12 months
- Valid for the branded and generic versions of KADIAN® manufactured by Actavis.

KADIAN 

Morphine Sulfate
Extended-Release Capsules

Drug Code: 3099-0100-0100-0100-0100

For more information about KADIAN®, please visit
www.KADIAN.com or call 1-877-637-4629

KAD1196 December 2011

Please read accompanying Full Prescribing Information

Bin #: 004682
Group #:
RxPCN: CN
ID #:

EXHIBIT 24

Dependent *Knoblauch*

Date *11/14/19* Rpt. *LS*

WWW.DEPOBOOKPRODUCTS.COM

PLAINTIFFS TRIAL
EXHIBIT

P-21999_00001

Patient Instructions: Use this card to reduce the amount due to an eligible third-party or cash prescription by presenting it to your pharmacist along with your valid prescription for KADIAN[®] or for the generic version of KADIAN[®] manufactured by Actavis. This card is not valid for generics from other companies. Keep this card and present it each time you have your prescription filled.

Pharmacist Instructions: Therapy First Plus has been authorized to reimburse you up to \$50 plus a handling fee. For reimbursement, please follow the below instructions:

To the Pharmacist for a patient paying cash: Please submit this claim to Therapy First Plus. A valid Other Coverage Code is required. The patient pay amount will be reduced by up to \$50, and you will receive this in your next reimbursement from Therapy First Plus, as well as a handling fee.

To the Pharmacist for a patient paying via an Authorized Third Party: Please submit to the Primary Third Party Payer first, then submit the balance due to Therapy First Plus as a Secondary Payer as a co-pay only billing. Other Coverage Code Indications Required. The pay amount will be reduced by up to \$50, and you will receive this in your next reimbursement from Therapy First Plus as well as a handling fee. Valid only at participating retail pharmacies in the US and Puerto Rico.

Not valid through mail-order pharmacies. This offer is limited up to one savings per prescription. This coupon card is not valid for prescriptions purchased under Medicaid, Medicare, federal or state programs (including state prescription drug programs, private indemnity or HMO insurance plans which reimburse you for the entire cost of your prescription drugs). This offer is not valid in Massachusetts, except for cash paying patients. Void where prohibited by law, taxed or restricted. Cash value: 1/20¢. Reproductions and/or alterations of coupon will not be accepted.

Pharmacists Only: For any questions regarding Therapy First Plus online processing, please call the Help Desk at 1-800-422-5504.

ACTAVIS reserves the right to rescind, revoke, or amend this program without notice. KADIAN[®] is a registered trademark of ACTAVIS.

Administered by
 MediMedia[®] Health

FAQ

The KADIAN® (morphine sulfate extended-release) Capsules \$50 Co-Pay Assistance Card FAQ sheet

Question: Do I have to call an 800 number or go onto the internet to activate the card?

Answer: No. The card is already active. Simply present the card to your pharmacist with a valid prescription for KADIAN® capsules to receive immediate savings.

Question: Do I have to present this card every time I have my KADIAN® prescription filled?

Answer: Yes. Present this card and your valid prescription to your pharmacist each time you have your KADIAN® prescription filled. This card is multi-use so remember to keep your card for future savings.

Question: What if I have a problem redeeming the \$50 Co-Pay Assistance Card at the pharmacy?

Answer: Please contact the Help Desk at 1-877-637-4629 or ask your pharmacist to call the Pharmacy Help Desk at 1-800-422-5604 to address this problem.

Question: Can I use the card with mail order programs?

Answer: No. You cannot use this card with participating mail order pharmacies. To find a local pharmacy that participates, please contact the Help Desk at 1-877-637-4629.

Question: What if I lose my KADIAN® Co-Pay Assistance Card?

Answer: Please call the Help Desk at 1-877-637-4629 to request a replacement card.

If you have any other questions on how to use your Co-Pay Assistance Card, please call 1-877-637-4629.

Please see Boxed WARNING on page 2, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

8

The KADIAN® (morphine sulfate extended-release) Capsules Co-Pay Assistance Program

• For patients with a prescription co-pay: Card covers all out of pocket expense for all co-pay costs up to \$50.

• For cash paying patients: Card covers the first \$50 of the cost of the prescription

Present this card with your KADIAN® prescription and insurance card, if applicable. You can use the same card with up to 24 prescriptions of KADIAN® over 12 months. The KADIAN® Co-Pay Assistance Card pays the first \$50 of the patient's co-pay or out-of-pocket cost. Patient is responsible for the remainder of the co-pay that is greater than \$50.

Terms and Conditions: Valid only at participating retail pharmacies in the US and Puerto Rico. Not valid through mail-order pharmacies. This offer is limited up to one savings per prescription. This coupon card is not valid for prescriptions purchased under Medicaid, Medicare, federal or state programs (including state prescription drug programs, private indemnity or HMO insurance plans which reimburse you for the entire cost of your prescription drugs). This offer is not valid in Massachusetts, except for cash paying patients. Void where prohibited by law, taxed or restricted. Actavis reserves the right to rescind, revoke or amend this offer without notice at any time.

Please see Boxed WARNING on page 2, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

9

Generic KADIAN®

(morphine sulfate extended-release) Capsules CII from Actavis.

• Produced and Packaged in the same facilities as the brand.

• Same Size, Color and Shape that existing KADIAN® patients are familiar with.

Available Immediately at:

- CVS	- A&P	- Express Scripts	- Publix
- Rite Aid	- Albertsons	- Mail Order	- Sam's Club
- Walmart	- Balls Food	- Kmart	- Sav-On
- Kroger	- Bartell Drug	- Longs	- Scott and White
- SuperValu	- Bi-Lo/Bruno	- Medicine Shoppe	- Southern Family Market
- Target	- CARE	- Meijer	- Stop & Shop
	- Discount Drug Mart	- OSCO	- Thrifty White
		- Price Chopper	- Wegman

Now valid for Generic KADIAN® from Actavis®

Use the Enclosed Card To Save Up To **\$1,200** per year toward your KADIAN® prescriptions.

The KADIAN® Co-Pay Assistance Program provides the first \$50 toward each prescription for up to 24 prescriptions over 12 months.

Please see Boxed WARNING on page 2, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

For questions about this program, please call the Help Desk at 1-877-637-4629. *Card is not valid for generics from other companies. See list of pharmacies carrying the Actavis generic on back page.



- No Expiration Date
- No Upfront Patient Cost

WHAT IS THE INDICATION FOR KADIAN® USE?

- KADIAN® capsules are an extended-release capsule taken by mouth of morphine sulfate that is used to manage moderate to severe pain that continues around-the-clock and is expected to last for an extended period of time.
- KADIAN® is NOT for use to treat pain that occurs once in a while ("as needed").
- KADIAN® is not indicated for pain in the immediate post-operative period (12-24 hours following surgery) for patients who have not taken drugs called opioids before.
- KADIAN® is not indicated for pain in the post-operative period if the pain is mild or not expected to persist for an extended period of time.

RISK AND SAFETY INFORMATION ABOUT KADIAN®

The BOXED WARNING in the prescribing information for Healthcare Providers states:

Rx only

WARNING:

KADIAN® contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. KADIAN® can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing KADIAN® in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.

KADIAN® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

KADIAN® Capsules are NOT for use as a prn analgesic.

KADIAN® 100 mg and 200 mg Capsules ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. Ingestion of these capsules or of the pellets within the capsules may cause fatal respiratory depression when administered to patients not already tolerant to high doses of opioids.

KADIAN® CAPSULES ARE TO BE SWALLOWED WHOLE OR THE CONTENTS OF THE CAPSULES SPRINKLED ON APPLE SAUCE. THE PELLETS IN THE CAPSULES ARE NOT TO BE CHEWED, CRUSHED, OR DISSOLVED DUE TO THE RISK OF RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.

Please see Boxed WARNING on this page, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

2

— Trim
- - - - Score and Fold

WHAT DOES THIS INFORMATION MEAN FOR YOU:

- KADIAN[®], which is a federally controlled substance (CII), can be abused by people who abuse prescription medicines or street drugs. To prevent theft, misuse, or abuse of KADIAN[®], keep it in a safe place. Do not give KADIAN[®] to anyone else. It may harm them or even cause death. After you stop taking KADIAN[®], flush any unused capsules down the toilet.
- Do not crush, dissolve, or chew KADIAN[®] capsules or the capsule contents before swallowing. Abuse of KADIAN[®] by crushing, chewing, snorting or injecting the dissolved product will result in the uncontrolled delivery of morphine and pose a significant risk to the abuser that could result in overdose or death.
- KADIAN[®] is NOT for use to treat pain that occurs once in a while ("as needed").
- KADIAN[®] 100 mg and 200 mg capsules are for use only in opioid tolerant patients. "Opioid tolerant" means that you regularly use another opioid medicine for constant pain and that your body is used to it. Ingesting KADIAN[®] 100 mg and 200 mg capsules when you are not opioid tolerant may cause serious breathing problems and death.

Do Not Take KADIAN[®] If:

- You have a known hypersensitivity (allergy) to morphine, morphine salts, or any of the ingredients in KADIAN[®] (See the accompanying Prescribing Information for a complete list of ingredients in KADIAN[®]).
- You are having an asthma attack or have severe asthma, trouble breathing, or lung problems.
- You have a bowel blockage called paralytic ileus.
- Do not take KADIAN[®] with alcohol, other opioids, or illicit drugs because dangerous additive effects may occur resulting in serious injury or death. In addition, alcohol can cause very high levels of morphine in your blood and you can die due to an overdose of morphine.

Please see Boxed WARNING on page 2, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

What are the Possible Side Effects of KADIAN[®]?

- KADIAN[®] can cause serious breathing problems that may be life-threatening, especially if KADIAN[®] is used in the wrong way. Call your healthcare professional or get medical help right away if your breathing slows down, you have shallow breathing, you feel faint, dizzy, confused, or have any unusual symptoms. These can be symptoms that you have taken too much KADIAN[®] or that the dose is too high for you. These symptoms may lead to serious problems or death if not treated right away.
- There is a chance of abuse or addiction with KADIAN[®].
- Serious allergic reactions, while extremely rare, have been reported with use of KADIAN[®]. Get medical help right away if you experience any symptoms of a severe allergic reaction, such as: feeling dizzy or faint, trouble breathing, chest pain, or swelling of the face, throat, or tongue.
- Do not drive or operate machinery or perform other potentially hazardous activities until you know how you react to this medicine or to a change in the dose.
- Serious side effects that may be associated with KADIAN[®] therapy are those observed with other opioid analgesics and include: respiratory depression, respiratory arrest, apnea, circulatory depression, cardiac arrest, hypotension, and/or shock.
- The less severe side effects seen on initiation of therapy with KADIAN[®] are also typical opioid side effects. The most frequent of these include drowsiness, dizziness, constipation, and nausea.
- Severe constipation could occur as a result of taking KADIAN[®] and appropriate laxatives, stool softeners, and other appropriate treatments should be started at the beginning of therapy.

Please see Boxed WARNING on page 2, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

WHAT ARE SOME OF THE OTHER RISKS ASSOCIATED WITH KADIAN[®]?

WARNINGS

- **Head Injury and Increased Intracranial Pressure:** The respiratory depressant effects of morphine may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. KADIAN[®] produces effects which may hide neurologic signs of further increases in pressure in patients with head injuries. Morphine should only be administered under such circumstances when considered essential and then with extreme care.
- **Hypotensive Effect:** KADIAN[®] may cause severe hypotension (low blood pressure). There is an added risk to patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume, or a concurrent administration of drugs such as phenothiazines or general anesthetics. KADIAN[®] may produce orthostatic hypotension and fainting in ambulatory patients. KADIAN[®], like all opioid analgesics, should be administered with caution to patients in circulatory shock, as vasodilation produced by the drug may further reduce cardiac output and blood pressure.
- **Interactions with CNS Depressants:** KADIAN[®] should be used with great caution and in reduced dosage in patients who are concurrently receiving other central nervous system depressants including sedatives or sleep aids, general anesthetics, phenothiazines, other tranquilizers, and alcohol because respiratory depression, low blood pressure, and profound sedation or coma may result.
- **Gastrointestinal Obstruction:** KADIAN[®] should not be given to patients with gastrointestinal obstruction (bowel blockage), particularly a type called paralytic ileus, as there is a risk of the product remaining in the stomach for an extended period and the subsequent release of a bolus of morphine when normal gut motility is restored. As with other solid morphine formulations diarrhea may reduce morphine absorption.

PRECAUTIONS

- **General:** Opioid analgesics have a narrow therapeutic index in certain patient populations, especially when combined with CNS depressant drugs, and should be reserved for cases

Please see Boxed WARNING on page 2, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

where the benefits of opioid pain medication outweigh the known risks of respiratory depression, altered mental state, and postural hypotension.

The administration of KADIAN[®] may obscure the diagnosis or clinical course in patients with acute abdominal conditions. KADIAN[®] may aggravate pre-existing convulsions in patients with convulsive disorders.

- **Cordotomy:** Patients taking KADIAN[®] who are scheduled for cordotomy or other interruption of pain transmission pathways should have KADIAN[®] ceased 24 hours prior to the procedure and the pain controlled by parenteral short-acting opioids. In addition, the post-procedure titration of analgesics for such patients should be individualized to avoid either over sedation or withdrawal syndromes.

- **Use in Pancreatic/Biliary Tract Disease:** KADIAN[®] may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis. Opioids may cause increases in the serum amylase level.

- **Tolerance and Physical Dependence:** Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and tolerance are not unusual during chronic opioid therapy.

Special Risk Groups

- KADIAN[®] should be administered with caution, and in reduced dosages in elderly or debilitated patients; patients with severe kidney or liver insufficiency; patients with Addison's disease; myxedema; hypothyroidism; prostatic hypertrophy or urethral stricture. Caution should also be exercised in the administration of KADIAN[®] to patients with CNS depression, toxic psychosis, acute alcoholism and delirium tremens, and convulsive disorders.

Please see Boxed WARNING on page 2, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

Drug Interactions

- There is a potential for combined effects when KADIAN[®] is used by patients who are also taking other drugs that have central nervous system depressant effects, including sedatives, sleep aids, anti-nausea agents, other pain relievers, tranquilizers, muscle relaxants, alcohol, diuretics, and cimetidine.
- KADIAN[®] should not be used by patients who take Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping the MAOI.

DOSAGE AND ADMINISTRATION – HOW TO USE KADIAN[®]

- Do not crush, dissolve, or chew KADIAN[®] capsules or the capsule contents before swallowing. Abuse of KADIAN[®] by crushing, chewing, snorting or injecting the dissolved product will result in the uncontrolled delivery of morphine and pose a significant risk to the abuser that could result in overdose or death.
- Do not stop taking KADIAN[®] or any other opioid without talking to your healthcare professional. KADIAN[®] can cause physical dependence. This means you could become sick with uncomfortable withdrawal symptoms because your body has become used to these medicines. Physical dependence is not the same as drug addiction. Your doctor can tell you more about the differences between physical dependence and drug addiction.

IT IS IMPORTANT TO REMEMBER THAT:

- These are not all the risks and side effects associated with KADIAN[®]. For more information, please contact your doctor.
- Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.



Please see Boxed WARNING on page 2, Important Safety Information on pages 2-7, and accompanying Full Prescribing Information.

Rx only

WARNING:


KADIAN® contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. KADIAN® can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing KADIAN® in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.

KADIAN® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

KADIAN® Capsules are NOT for use as a prn analgesic.

KADIAN® 100 mg and 200 mg Capsules ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. Ingestion of these capsules or of the pellets within the capsules may cause fatal respiratory depression when administered to patients not already tolerant to high doses of opioids.

KADIAN® CAPSULES ARE TO BE SWALLOWED WHOLE OR THE CONTENTS OF THE CAPSULES SPRINKLED ON APPLE SAUCE. THE PELLETS IN THE CAPSULES ARE NOT TO BE CHEWED, CRUSHED, OR DISSOLVED DUE TO THE RISK OF RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.



For further product information, please visit www.KADIAN.com or call 1-888-496-3082. Please see accompanying Full Prescribing Information. KADIAN® is a registered trademark of Actavis Elizabeth LLC.



©2011 Actavis Elizabeth LLC. All rights reserved. KAD11198 December 2011 Printed in USA




KADIAN®
Co-Pay Assistance Program



Please see Boxed WARNING on reverse side of this stand. Please see accompanying product information, including Boxed WARNING, with each brochure.

For questions about this program, please call the Help Desk at 1-877-637-4629.



Title:

**ADVERTISEMENT & PROMOTION
REVIEW/APPROVAL**

Number:

FRA-003A

Review Date	December 28, 2011
Job Description	Revised Co-Pay Card (Branded and Generic)
Job Code	KADI1196
Target Audience	Healthcare Professionals and Patients
Method of Delivery	Salesforce Delivery
New or Revised	<input type="checkbox"/> New <input checked="" type="checkbox"/> Revised from Job Code _____ Comment: _____
Package Insert Required	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Leave Behind	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Template:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Comments	Updated from job code KADI1175. Program now includes generic Kadian
DDMAC Submission Required	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

PRC (Promotional Review Committee) Approval Sign Off

Print Name	Dept	Signature	Date
	Legal		
	Regulatory		
	Medical Consult*		
	Expert Consult*		
<input type="checkbox"/> Amend and Re-circulate (Check box if applicable)			


*Indicate "not applicable" or "NA" in the signature space if consult not required for the piece.

Marketing Sign-Off

Print Name	Signature	Date
Jennifer Thier	<i>Jennifer Thier</i>	12/28/11
Approved		

Regulatory Release Sign Off

Print Name	Signature	Date



Title:

ADVERTISEMENT & PROMOTION
REVIEW/APPROVAL

Number:

FRA-003A

Review Date	December 28, 2011
Job Description	Revised Co-Pay Card Brochure (Branded and Generic)
Job Code	KADI1197
Target Audience	Healthcare Professionals and Patients
Method of Delivery	Salesforce Delivery
New or Revised	<input type="checkbox"/> New <input checked="" type="checkbox"/> Revised from Job Code _____ Comment: _____
Package Insert Required	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Leave Behind	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Template:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Comments	Updated from job code KADI1174. Program now includes generic Kadian
DDMAC Submission Required	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

PRC (Promotional Review Committee) Approval Sign Off

Print Name	Dept	Signature	Date
	Legal		
	Regulatory		
	Medical Consult*		
	Expert Consult*		

Amend and Re-circulate (Check box if applicable)

*Indicate "not applicable" or "NA" in the signature space if consult not required for the piece.

Marketing Sign-Off

Print Name	Signature	Date
Jennifer Ather	<i>Jennifer Ather</i>	12-28-11
Approved		

Regulatory Release Sign Off

Print Name	Signature	Date



Title:

**ADVERTISEMENT & PROMOTION
REVIEW/APPROVAL**

Number:

FRA-003A

Review Date	December 28, 2011
Job Description	Revised Co-Pay Card Brochure Stand (Branded and Generic)
Job Code	KADI1198
Target Audience	Healthcare Professionals and Patients
Method of Delivery	Salesforce Delivery
New or Revised	<input type="checkbox"/> New <input checked="" type="checkbox"/> Revised from Job Code _____ Comment: _____
Package Insert Required	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Leave Behind	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Template:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Comments	Updated from job code KADI1181. Program now includes generic Kadian
DDMAC Submission Required	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

PRC (Promotional Review Committee) Approval Sign Off

Print Name	Dept	Signature	Date
	Legal		
	Regulatory		
	Medical Consult*		
	Expert Consult*		

Amend and Re-circulate (Check box if applicable)

*Indicate "not applicable" or "NA" in the signature space if consult not required for the piece.

Marketing Sign-Off

Print Name	Signature	Date
Jennifer Altier		12/28/11
Approved		

Regulatory Release Sign Off

Print Name	Signature	Date